Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY25 results · Jul–Sep 2024
Sun Pharma Advanced Research Company reported revenue from operations of ₹12.86 crore (down 39.3% from Q2 FY24) and net loss of ₹107.33 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 12.86 | 21.18 | −39.3% | 16.81 | −23.5% |
| Other income | 0.04 | 8.49 | −99.5% | 1.56 | −97.4% |
| Total income | 12.90 | 29.67 | −56.5% | 18.37 | −29.8% |
| Profit before tax | (107.17) | (86.42) | Loss widened | (95.50) | Loss widened |
| Net profit for the period | (107.33) | (86.42) | Loss widened | (95.90) | Loss widened |
| Attributable to shareholders of the company | (107.28) | (86.42) | Loss widened | — | — |
| EPS, basic (₹) | (3.31) | (2.66) | Loss widened | (2.96) | Loss widened |
| Net margin (%) | -834.6 | -408.0 | -570.5 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 12.86 | 21.18 | −39.3% | 16.81 | −23.5% |
| Other income | 0.04 | 8.49 | −99.5% | 1.56 | −97.4% |
| Total income | 12.90 | 29.67 | −56.5% | 18.37 | −29.8% |
| Profit before tax | (107.69) | (86.42) | Loss widened | (96.84) | Loss widened |
| Net profit for the period | (107.69) | (86.42) | Loss widened | (96.84) | Loss widened |
| EPS, basic (₹) | (3.32) | (2.66) | Loss widened | (2.98) | Loss widened |
| Net margin (%) | -837.4 | -408.0 | -576.1 |
Consolidated
- Filed with BSE
- 04 Nov 2024, 15:25 IST
- Board meeting
- 04 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2024, 15:25 IST
- Board meeting
- 04 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE